A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen

作者：Miyata Yoshiharu^*; Yakushijin Kimikazu; Inui Yumiko; Imamura Yoshinori; Goto Hideaki; Mizutani Yu; Kurata Keiji; Kakiuchi Seiji; Sanada Yukinari; Minami Yosuke; Kawamoto Shinichiro; Yamamoto Katsuya; Ito Mitsuhiro; Tominaga Ryo; Gomyo Hiroshi; Mizuno Ishikazu; Nomura Tetsuhiko; Kitagawa Koichi; Sugimoto Takeshi; Murayama Tohru; Matsuoka Hiroshi; Minami Hironobu

来源：International Journal of Hematology, 2016, 104(6): 682-691.

DOI：10.1007/s12185-016-2089-9

• Chemotherapy-induced nausea and vomiting
• Malignant lymphoma
• CHOP
• Palonosetron
• 5-HT3 receptor antagonist

To identify strategies for reducing emesis induced by the CHOP regimen, which includes high-dose steroids, we prospectively evaluated the efficacy of palonosetron in Japanese patients. Palonosetron was administered at a dose of 0.75 mg via intravenous injection over 30 min before chemotherapy on day 1. Patients kept diaries of chemotherapy-induced nausea and vomiting (CINV) incidence from the start of chemotherapy until 168 h afterwards, in which they documented the occurrence and severity of nausea, vomiting, anorexia, and the use of rescue medication. The primary endpoint was the overall occurrence rate of nausea, vomiting, and anorexia; these rates were 56, 12, and 62 %, respectively, including all grades. The rates and severity of symptoms tended to worsen 120-168 h after completing oral prednisolone. We defined complete response (CR) as no vomiting and no use of rescue therapy. The CR rates of post palonosetron 0.75 mg treatment in the acute (0-24 h), delayed (24-168 h), and overall phases (0-168 h) were 86, 66, and 62 %, respectively. Antiemetic strategies of CHOP regimen for day 6 and, thereafter, should be investigated.

• 出版日期2016-12